Who are Chlorhexidine mouthwash (0.2%)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Silvadene, daptomycin (up to 14 days), Chlorhexidine rinse, chlorhexidine digluconate, A (Chloraprep), adapalene/benzoyl peroxide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chlorhexidine-mouthwash-0-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Chlorhexidine mouthwash (0.2%) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chlorhexidine mouthwash (0.2%) (Chlorhexidine mouthwash (0.2%)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial oral rinse / Antiseptic. Area: Dentistry / Oral Health.

phase 3 Antimicrobial oral rinse / Antiseptic Bacterial cell membrane Dentistry / Oral Health Small molecule Live · refreshed every 30 min

Target snapshot

Chlorhexidine mouthwash (0.2%) (Chlorhexidine mouthwash (0.2%)) — Al-Mustansiriyah University. Chlorhexidine mouthwash disrupts bacterial cell membranes and precipitates bacterial proteins, providing broad-spectrum antimicrobial activity in the oral cavity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Chlorhexidine mouthwash (0.2%) TARGET	Chlorhexidine mouthwash (0.2%)	Al-Mustansiriyah University	phase 3	Antimicrobial oral rinse / Antiseptic	Bacterial cell membrane
Silvadene	Silver Sulfadiazine	Pfizer	marketed	sulfonamide antimicrobial	bacterial cell membrane and cell wall	1973-01-01
daptomycin (up to 14 days)	daptomycin (up to 14 days)	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	marketed	Cyclic lipopeptide antibiotic	Bacterial cell membrane
Chlorhexidine rinse	Chlorhexidine rinse	Universidade Estadual Paulista Júlio de Mesquita Filho	marketed	Antimicrobial oral rinse	Bacterial cell membrane and proteins
chlorhexidine digluconate	chlorhexidine digluconate	Universidade Federal do Ceara	marketed	Antimicrobial agent / Antiseptic	Bacterial cell membrane and proteins
A (Chloraprep)	A (Chloraprep)	Instituto de Investigacion Sanitaria La Fe	marketed	Topical antiseptic	Bacterial cell membrane and proteins
adapalene/benzoyl peroxide	adapalene/benzoyl peroxide	Galderma R&D	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial oral rinse / Antiseptic class)

Al-Mustansiriyah University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Chlorhexidine mouthwash (0.2%) — Competitive Intelligence Brief. https://druglandscape.com/ci/chlorhexidine-mouthwash-0-2. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab